Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BNTX NASDAQ:INSM NASDAQ:KYMR NASDAQ:ROIV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNTXBioNTech$95.95+2.7%$94.46$79.52▼$124.00$24.26B1.36893,257 shs1.37 million shsINSMInsmed$106.91-1.3%$134.42$65.56▼$212.75$23.17B0.894.14 million shs4.53 million shsKYMRKymera Therapeutics$81.420.0%$83.33$28.50▼$103.00$6.70B2.06457,042 shs587,343 shsROIVRoivant Sciences$29.99+0.4%$28.63$10.59▼$32.79$21.46B1.146.28 million shs7.73 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNTXBioNTech0.00%+4.14%-7.25%-12.95%-1.62%INSMInsmed0.00%+0.63%-21.58%-28.41%+61.11%KYMRKymera Therapeutics0.00%+3.21%+0.43%-10.87%+182.71%ROIVRoivant Sciences0.00%+0.10%+5.12%+3.63%+182.39%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNTXBioNTech$95.95+2.7%$94.46$79.52▼$124.00$24.26B1.36893,257 shs1.37 million shsINSMInsmed$106.91-1.3%$134.42$65.56▼$212.75$23.17B0.894.14 million shs4.53 million shsKYMRKymera Therapeutics$81.420.0%$83.33$28.50▼$103.00$6.70B2.06457,042 shs587,343 shsROIVRoivant Sciences$29.99+0.4%$28.63$10.59▼$32.79$21.46B1.146.28 million shs7.73 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNTXBioNTech0.00%+4.14%-7.25%-12.95%-1.62%INSMInsmed0.00%+0.63%-21.58%-28.41%+61.11%KYMRKymera Therapeutics0.00%+3.21%+0.43%-10.87%+182.71%ROIVRoivant Sciences0.00%+0.10%+5.12%+3.63%+182.39%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBNTXBioNTech 2.74Moderate Buy$129.5635.03% UpsideINSMInsmed 2.96Moderate Buy$210.9597.32% UpsideKYMRKymera Therapeutics 2.95Moderate Buy$118.1045.04% UpsideROIVRoivant Sciences 2.75Moderate Buy$33.5912.01% UpsideCurrent Analyst Ratings BreakdownLatest KYMR, BNTX, INSM, and ROIV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2026BNTXBioNTech UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$117.00 ➝ $135.005/26/2026ROIVRoivant Sciences GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$30.00 ➝ $36.005/22/2026ROIVRoivant Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)5/21/2026BNTXBioNTech Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Perform$96.005/21/2026ROIVRoivant Sciences Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight5/21/2026ROIVRoivant Sciences TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$38.00 ➝ $41.005/21/2026ROIVRoivant Sciences CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$35.00 ➝ $42.005/21/2026ROIVRoivant Sciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$34.005/21/2026ROIVRoivant Sciences Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$42.005/21/2026BNTXBioNTech Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold5/13/2026INSMInsmed Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$205.00 ➝ $185.00(Data available from 5/31/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBNTXBioNTech$3.25B7.47$1.34 per share71.87$86.54 per share1.11INSMInsmed$819.56M28.27N/AN/A$3.25 per share32.90KYMRKymera Therapeutics$39.21M170.81N/AN/A$18.72 per share4.35ROIVRoivant Sciences$8.26M2,598.53N/AN/A$7.39 per share4.06Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBNTXBioNTech-$1.29B-$5.88N/AN/AN/A-44.39%-5.30%-4.62%8/3/2026 (Estimated)INSMInsmed-$1.28B-$5.75N/A124.31N/A-144.44%-130.11%-51.57%8/6/2026 (Estimated)KYMRKymera Therapeutics-$311.35M-$3.57N/AN/AN/A-611.94%-24.71%-22.05%8/10/2026 (Estimated)ROIVRoivant Sciences-$299.77M-$0.60N/AN/AN/A-3,629.19%-20.54%-19.43%8/10/2026 (Estimated)Latest KYMR, BNTX, INSM, and ROIV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2026Q4 2026ROIVRoivant Sciences-$0.2893$0.28+$0.5693$0.28$3.41 million$2.52 million5/7/2026Q1 2026INSMInsmed-$0.90-$0.76+$0.14-$0.76$300.81 million$305.96 million5/4/2026Q1 2026BNTXBioNTech-$2.52-$2.2570+$0.2630-$2.43$207.42 million$136.71 million4/30/2026Q1 2026KYMRKymera Therapeutics-$0.89-$0.71+$0.18-$0.71$8.27 million$34.37 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBNTXBioNTechN/AN/AN/AN/AN/AINSMInsmedN/AN/AN/AN/AN/AKYMRKymera TherapeuticsN/AN/AN/AN/AN/AROIVRoivant SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBNTXBioNTech0.018.808.74INSMInsmed0.804.474.10KYMRKymera TherapeuticsN/A10.8110.81ROIVRoivant SciencesN/A18.3718.37Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBNTXBioNTech15.52%INSMInsmedN/AKYMRKymera TherapeuticsN/AROIVRoivant Sciences64.76%Insider OwnershipCompanyInsider OwnershipBNTXBioNTech19.20%INSMInsmed2.10%KYMRKymera Therapeutics15.98%ROIVRoivant Sciences10.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBNTXBioNTech7,807252.88 million204.33 millionOptionableINSMInsmed1,664216.75 million212.20 millionOptionableKYMRKymera Therapeutics17082.26 million69.11 millionOptionableROIVRoivant Sciences860715.70 million638.41 millionOptionableKYMR, BNTX, INSM, and ROIV HeadlinesRecent News About These CompaniesRoivant Sciences Ltd. (ROIV) Presents at Bernstein 42nd Annual Strategic Decisions Conference TranscriptMay 29 at 6:01 PM | seekingalpha.comAssessing Roivant Sciences (ROIV) Valuation After Strong Recent Share Price MomentumMay 26, 2026 | finance.yahoo.comTD Cowen Raises its Price Target on Roivant Sciences (ROIV)May 25, 2026 | finance.yahoo.comLitigation Windfall Driving Roivant Sciences’ Profit Swing Might Change The Case For Investing In Roivant Sciences (ROIV)May 25, 2026 | finance.yahoo.com5 High Growth Stocks to Buy and Hold for the Next DecadeMay 25, 2026 | insidermonkey.comBlue Owl Capital Holdings LP Sells 725,000 Shares of Roivant Sciences Ltd. $ROIVMay 25, 2026 | marketbeat.comJefferies Financial Group Inc. Purchases Shares of 3,514,833 Roivant Sciences Ltd. $ROIVMay 24, 2026 | marketbeat.comEric Venker Sells 200,000 Shares of Roivant Sciences (NASDAQ:ROIV) StockMay 23, 2026 | insidertrades.comAnalysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN) and Roivant Sciences (ROIV)May 22, 2026 | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV) and Citius Oncology (CTOR)May 22, 2026 | theglobeandmail.comRoivant Sciences (NASDAQ:ROIV) Posts Earnings Results, Beats Estimates By $0.57 EPSMay 21, 2026 | marketbeat.comRoivant Sciences Ltd. (NASDAQ:ROIV) Q4 2025 Earnings Call TranscriptMay 21, 2026 | insidermonkey.comRoivant Sciences Ltd. 2025 Q4 - Results - Earnings Call PresentationMay 21, 2026 | seekingalpha.comRoivant Sciences (NASDAQ:ROIV) Hits New 52-Week High on Earnings BeatMay 21, 2026 | marketbeat.comRoivant (ROIV) Climbs 15% on Swing to ProfitsMay 20, 2026 | insidermonkey.comRoivant anticipates $950M Moderna payment in July as it outlines 2H 2026 mosliciguat and IMVT-1402 readoutsMay 20, 2026 | seekingalpha.comRoivant Sciences Ltd (ROIV) Q4 2025 Earnings Call Highlights: Strategic Settlements and ...May 20, 2026 | finance.yahoo.comRoivant (ROIV) Climbs 15% on Swing to ProfitsMay 20, 2026 | finance.yahoo.comRoivant Sciences Earnings Call Highlights High-Impact PipelineMay 20, 2026 | tipranks.comRoivant Sciences Ltd. (ROIV) Q4 2025 Earnings Call TranscriptMay 20, 2026 | seekingalpha.comRoivant Shares Climb on Earnings Beat Despite Revenue Shortfall (ROIV)May 20, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKYMR, BNTX, INSM, and ROIV Company DescriptionsBioNTech NASDAQ:BNTX$95.95 +2.51 (+2.69%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$96.00 +0.05 (+0.05%) As of 05/29/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.Insmed NASDAQ:INSM$106.91 -1.46 (-1.35%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$107.84 +0.93 (+0.87%) As of 05/29/2026 05:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.Kymera Therapeutics NASDAQ:KYMR$81.42 -0.04 (-0.05%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$81.39 -0.03 (-0.04%) As of 05/29/2026 05:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Roivant Sciences NASDAQ:ROIV$29.99 +0.11 (+0.37%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$29.36 -0.63 (-2.12%) As of 05/29/2026 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/25 - 05/29 Gap Inc. Cuts Sales Outlook After Q1 Miss, Shares Drop 17% Costco’s Strong Quarter Still Leaves Investors With a Valuation Problem MongoDB's AI Advantage Is Starting to Show Up in Results 3 Ways to Play the Data Center Land Grab Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys Dollar Tree Keeps Winning After Family Dollar Divorce Salesforce Stock Finds Support as AI Momentum Builds Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
